Erasca Inc (NASDAQ: ERAS) has seen a rise in its stock price by 1.40 in relation to its previous close of 1.42. However, the company has experienced a 33.80% gain in its stock price over the last five trading sessions. globenewswire.com reported 2025-06-02 that Both ERAS-4001 and potential best-in-class pan-RAS molecular glue ERAS-0015 received IND clearance in May ahead of company guidance Initial Phase 1 monotherapy data for both RAS-targeting programs expected in 2026 SAN DIEGO, June 02, 2025 (GLOBE NEWSWIRE) — Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced clearance of an investigational new drug (IND) application by the United States Food and Drug Administration (FDA) for ERAS-4001, a potential first-in-class and best-in-class pan-KRAS inhibitor, for the treatment of patients with KRAS-mutant (KRASm) solid tumors. “Our RAS-targeting franchise continues to meaningfully advance, and now with clearance of our IND for ERAS-4001, we are excited to advance both ERAS-4001 and ERAS-0015 into the clinic ahead of our guidance,” said Jonathan E.
Is It Worth Investing in Erasca Inc (NASDAQ: ERAS) Right Now?
The stock has a 36-month beta value of 1.09. Opinions on the stock are mixed, with 5 analysts rating it as a “buy,” 3 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for ERAS is 160.60M, and at present, short sellers hold a 13.07% of that float. On June 04, 2025, the average trading volume of ERAS was 1.71M shares.
ERAS’s Market Performance
ERAS’s stock has seen a 33.80% increase for the week, with a -8.54% drop in the past month and a 9.47% gain in the past quarter. The volatility ratio for the week is 14.08%, and the volatility levels for the past 30 days are at 8.64% for Erasca Inc The simple moving average for the past 20 days is 11.76% for ERAS’s stock, with a -32.15% simple moving average for the past 200 days.
Analysts’ Opinion of ERAS
Many brokerage firms have already submitted their reports for ERAS stocks, with Raymond James repeating the rating for ERAS by listing it as a “Outperform.” The predicted price for ERAS in the upcoming period, according to Raymond James is $5 based on the research report published on March 26, 2025 of the current year 2025.
Jefferies, on the other hand, stated in their research note that they expect to see ERAS reach a price target of $6. The rating they have provided for ERAS stocks is “Buy” according to the report published on November 18th, 2024.
CapitalOne gave a rating of “Overweight” to ERAS, setting the target price at $8 in the report published on March 11th of the previous year.
ERAS Trading at 9.85% from the 50-Day Moving Average
After a stumble in the market that brought ERAS to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -58.12% of loss for the given period.
Insider Trading
Reports are indicating that there were more than several insider trading activities at ERAS starting from Erasca Foundation, who proposed sale 8,333 shares at the price of $1.19 back on May 15 ’25. After this action, Erasca Foundation now owns shares of Erasca Inc, valued at $9,902 using the latest closing price.
Erasca Foundation, the Affiliate of Erasca Inc, proposed sale 8,333 shares at $1.22 during a trade that took place back on Apr 15 ’25, which means that Erasca Foundation is holding shares at $10,165 based on the most recent closing price.
Stock Fundamentals for ERAS
The total capital return value is set at -0.35. Equity return is now at value -45.82, with -37.47 for asset returns.
Based on Erasca Inc (ERAS), the company’s capital structure generated 0.11 points at debt to capital in total, while cash flow to debt ratio is standing at -2.12.
Currently, EBITDA for the company is -157.84 million with net debt to EBITDA at 0.13. The liquidity ratio also appears to be rather interesting for investors as it stands at 12.35.
Conclusion
To sum up, Erasca Inc (ERAS) has seen a mixed performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
